《彭博通讯社》引述消息报道，血液制品和生物医药商泰邦生物已选定中公司及摩通，为其安排於本港首次公开招股(IPO)，预期最快明年挂牌，估值或高达60亿美元。泰邦生物的总部位於北京，曾於纽约交易所上市，至2021年被由大钲资本牵头的财团私有化而退市，该财团的参与方还包括中信资本、高瓴资本及淡马锡等，当时估值48亿美元。其後，公司曾透露可能将於香港重新上市。公司上周二(2日)宣布，由阿布扎比投资局旗下全资子公司Platinum Orchid、新加坡主权财富基金新加坡政府投资公司(GIC)领投，获得融资3亿美元。根据泰邦生物官网，集团於2002年成立，核心业务包括血液制品和生物制品的研发、生产和销售，涵盖人血白蛋白、人免疫球蛋白和人凝血因子三大类、20多个品规的血液制品的产品线。(jl/da)~阿思达克财经新闻网址: www.aastocks.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.